CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Cash flows from operating activities:
Net loss	$ (226,064)	$ (165,794)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	23,163	9,941
Non-cash operating lease costs	12,869	10,091
Amortization of deferred commissions	17,672	13,201
Stock-based compensation, net of amounts capitalized	264,509	172,493
Net amortization (accretion) of premiums (discounts) on investments	(15,331)	8,198
Net unrealized losses on strategic investments in equity securities	2,414	8,859
Deferred income tax	(8,868)	(26,664)
Other	9,978	1,761
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	362,893	266,656
Deferred commissions	(16,440)	(16,718)
Prepaid expenses and other assets	5,527	(57,535)
Accounts payable	(3,093)	4,158
Accrued expenses and other liabilities	(8,542)	(14,217)
Operating lease liabilities	(10,763)	(8,376)
Deferred revenue	(110,480)	(21,441)
Net cash provided by operating activities	299,444	184,613
Cash flows from investing activities:
Purchases of property and equipment	(6,970)	(7,413)
Capitalized internal-use software development costs	(9,341)	(4,804)
Cash paid for business combinations, net of cash, cash equivalents, and restricted cash acquired	(123,112)	(177,925)
Purchases of investments	(1,037,286)	(897,291)
Sales of investments	5,652	10,974
Maturities and redemptions of investments	808,844	886,667
Net cash used in investing activities	(362,213)	(189,792)
Cash flows from financing activities:
Proceeds from exercise of stock options	15,370	15,276
Proceeds from issuance of common stock under employee stock purchase plan	37,065	26,094
Taxes paid related to net share settlement of equity awards	(84,399)	(53,216)
Repurchases of common stock	(191,694)	0
Net cash used in financing activities	(223,658)	(11,846)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	535	(5,098)
Net decrease in cash, cash equivalents, and restricted cash	(285,892)	(22,123)
Cash, cash equivalents, and restricted cash—beginning of period	956,731	1,102,534
Cash, cash equivalents, and restricted cash—end of period	670,839	1,080,411
Supplemental disclosures of non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	8,071	4,782
Stock-based compensation included in capitalized software development costs	11,719	6,291
Issuance of common stock in connection with a business combination	0	438,916
Unpaid taxes related to net share settlement of equity awards included in accrued expenses and other current liabilities	4,657	928
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	653,014	1,063,401
Restricted cash—included in other assets and prepaid expenses and other current assets	17,825	17,010
Total cash, cash equivalents, and restricted cash	$ 670,839	$ 1,080,411